The content is available as a PDF (518.7 KB).
letter . 2021 Aug 11:jiab406. doi: 10.1093/infdis/jiab406
SARS-CoV-2 Specific Monoclonal Antibody for the Treatment of Mild-to-Moderate COVID-19 in Cancer Patients: A Single-center Experience
Alfredo G Puing
1,✉, Stephanie Ho
2, Paul Frankel
3, Bernard Tegtmeier
1, Abigail Martin
1, Justine Ross
2, Deepa Nanayakkara
1, Jana Dickter
1, Tyler Seto
4, Ryotaro Nakamura
5, Randy Taplitz
1, Sanjeet Dadwal
1
Alfredo G Puing, MD
1Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center, Duarte, CA, USA
Find articles by Alfredo G Puing
Stephanie Ho, PharmD
2Department of Pharmacy Services, City of Hope National Medical Center, Duarte, CA, USA
Find articles by Stephanie Ho
Paul Frankel, PhD
3Division of Biostatistics, Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA, USA
Find articles by Paul Frankel
Bernard Tegtmeier, PhD
1Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center, Duarte, CA, USA
Find articles by Bernard Tegtmeier
Abigail Martin, NP
1Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center, Duarte, CA, USA
Find articles by Abigail Martin
Justine Ross, PharmD
2Department of Pharmacy Services, City of Hope National Medical Center, Duarte, CA, USA
Find articles by Justine Ross
Deepa Nanayakkara, MD
1Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center, Duarte, CA, USA
Find articles by Deepa Nanayakkara
Jana Dickter, MD
1Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center, Duarte, CA, USA
Find articles by Jana Dickter
Tyler Seto, MD
4Department of Quality, Risk and Regulatory Management, City of Hope National Medical Center, Duarte, CA, USA
Find articles by Tyler Seto
Ryotaro Nakamura, MD
5Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA
Find articles by Ryotaro Nakamura
Randy Taplitz, MD
1Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center, Duarte, CA, USA
Find articles by Randy Taplitz
Sanjeet Dadwal, MD
1Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center, Duarte, CA, USA
Find articles by Sanjeet Dadwal
1Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center, Duarte, CA, USA
2Department of Pharmacy Services, City of Hope National Medical Center, Duarte, CA, USA
3Division of Biostatistics, Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA, USA
4Department of Quality, Risk and Regulatory Management, City of Hope National Medical Center, Duarte, CA, USA
5Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA
✉
Correspondence: Alfredo Puing, MD, City of Hope National Medical Center, Division of Infectious Diseases, 1500 E Duarte Rd, Duarte, CA 91010, Phone 626-218-5096, Fax 626-218-8954, E-mail: apuing@coh.org
Received 2021 Jul 23.
Keywords: COVID-19, monoclonal antibody, cancer, immunocompromised
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
PMCID: PMC8385995 PMID: 34379763